[The results of using differentiated programs of therapy in acute lymphoblastic leukemia in adults].

Results of the treatment of 30 adult patients with acute lymphoblastic leukemia are analyzed. Before the treatment was commenced, the patients were distributed into groups with a favourable, intermediate and unfavourable prognosis depending on the signs previously defined by the authors. In the phase of induction and consolidation of a remission, the treatment intensity in these groups varied.

[Monoclonal antibodies ICO-11 in the prognostic evaluation of acute nonlymphoblastic leukemia].

The antigen detectable with monoclonal antibodies ICO-11 was studied in cells of 33 patients with acute lymphoblastic leukemia (ALL) and 47 patients with acute non-lymphoblastic leukemia (ANLL). The incidence rate of antigen-positive cases in ALL comprised 39.4%, in ANLL 35.

Two different anti-erythroid monoclonal antibodies in immunodiagnosis of human leukemias: a comparative study.

To date, only anti-glycophorin-A monoclonal antibodies (MAbs) have been widely used as anti-erythroid probes in the diagnosis of leukemias. We have examined blood, bone-marrow and lymph-node samples from 474 patients, adults and children, with different hemopoietic malignancies, using a panel of MAbs including 2 anti-erythroid MAbs directed to glycophorin-A and an antigen of erythroblasts, Ag-Eb. MAb HAE9 directed against a human epitope of Ag-Eb has earlier been shown to be highly specific for immature erythroid cells.